PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30326170-1 2019 Delta-9-tetrahydrocannabinol (THC), the main psychoactive cannabinoid in cannabis, may inhibit the cytochrome P450 enzyme CYP2C9. Dronabinol 0-28 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 122-128 31433338-6 2019 FINDINGS: After comparing the in vitro inhibition parameters to physiologically achievable cannabinoid concentrations, it was concluded that CYP2C9, CYP1A1/2, and CYP1B1 are likely to be inhibited by all 3 major cannabinoids Delta-tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN). Dronabinol 253-256 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 141-147 31048453-7 2019 CYP2C9 pathway was the major pathway for depletion of THC (fm = 0.91, Km,u = 3 nM) and formation of 11-OH-THC. Dronabinol 54-57 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 30326170-1 2019 Delta-9-tetrahydrocannabinol (THC), the main psychoactive cannabinoid in cannabis, may inhibit the cytochrome P450 enzyme CYP2C9. Dronabinol 30-33 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 122-128 30326170-6 2019 The in vitro study indicated that THC inhibits the CYP2C9-mediated metabolism of warfarin. Dronabinol 34-37 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 51-57 26409163-8 2015 The in-vitro metabolism assay with the human CYP2C9 isoform led to the formation of THCOH and THCCOOH of Delta(8)-THC and Delta(9)-THC. Dronabinol 122-134 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 45-51 26267945-4 2015 Cytochromes P450 (CYP) 2C9 and 3A4 are involved in the metabolism of tetrahydrocannabinol and cannabidiol, which implies possible DDI with CYP450 inhibitor and inducer, such as anticonvulsivants and HIV protease inhibitors, which may be prescribed in patients with neuropathic pain. Dronabinol 69-89 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-26 17303175-4 2007 Human CYP2C9-Arg expressed in the microsomes of human B lymphoblastoid cells efficiently catalyzed the 11-hydroxylation of Delta(8)-THC (7.60 nmol/min/nmol CYP), Delta(9)-THC (19.2 nmol/min/nmol CYP) and CBN (6.62 nmol/min/nmol CYP). Dronabinol 162-174 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 6-12 19005461-0 2009 Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Dronabinol 53-80 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 120-126 19005461-1 2009 The impact of the CYP2C9 polymorphism on the pharmacokinetics of orally administered 9-tetrahydrocannabinol (THC) was studied in 43 healthy volunteers. Dronabinol 85-107 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 18-24 19005461-3 2009 However, the median area under the curve of THC was threefold higher and that of 11-nor-9-carboxy-9-tetrahydrocannabinol was 70% lower in CYP2C9*3/*3 homozygotes than in CYP2C9*1/*1 homozygotes. Dronabinol 44-47 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 138-144 19005461-4 2009 CYP2C9*3 carriers also showed a trend toward increased sedation following administration of THC. Dronabinol 92-95 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 19005461-5 2009 Therefore, the CYP2C9*3 variant may influence both the therapeutic and adverse effects of THC. Dronabinol 90-93 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 15-21 24160757-5 2014 Clinical pharmacogenetic data further support CYP2C9 as a significant contributor to THC metabolism, and a pharmacokinetic interaction study using ketoconazole with oromucosal cannabis extract further supports CYP3A4 as a significant metabolic pathway for THC and CBD. Dronabinol 85-88 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 46-52 31114948-2 2019 Cytochrome P450 (CYP) 2C9, the primary enzyme responsible for THC metabolism, has two single nucleotide polymorphisms-Arg144Cys (*2) and Ile359Leu (*3). Dronabinol 62-65 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-25 31114948-6 2019 We therefore sought to characterize the pharmacokinetics of THC and its major metabolites 11-hydroxy-delta-9-tetrahydrocannabinol (THC-OH) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THC-COOH) in healthy volunteers with known CYP2C9 status by non-compartmental analysis (NCA), compartmental modeling (CM) and minimal physiologically based pharmacokinetic (mPBPK) modeling. Dronabinol 60-63 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 233-239 31114948-11 2019 THC hepatic clearance is dependent on the CYP2C9 genetic variant in the population. Dronabinol 0-3 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 42-48 31114948-15 2019 THC-COOH is glucuronidated and renally cleared; subjects homozygous for CYP2C9*3 have reduced exposure to this metabolite as a result of the polymorphism reducing THC production, the hepatic diffusional barrier impeding egress from the hepatocyte, and increased renal clearance. Dronabinol 0-3 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 72-78 31114948-15 2019 THC-COOH is glucuronidated and renally cleared; subjects homozygous for CYP2C9*3 have reduced exposure to this metabolite as a result of the polymorphism reducing THC production, the hepatic diffusional barrier impeding egress from the hepatocyte, and increased renal clearance. Dronabinol 163-166 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 72-78 31114948-16 2019 CONCLUSION: It has recently been reported that the terminal metabolite THC-COOH is active, implying the exposure difference in individuals homozygous for CYP2C9*3 may become therapeutically relevant. Dronabinol 71-74 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 154-160 16112652-0 2005 CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Dronabinol 16-43 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-5 16112652-4 2005 The present study was designed to address the kinetics and pharmacogenetics of CYP2C-mediated metabolism of (delta9)-THC by studying its metabolism in human liver microsomes and expressed enzymes. Dronabinol 108-120 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 79-84 16112652-5 2005 Expressed CYP2C9.1 exhibited high affinity for the hydroxylation of delta9-THC (apparent Km, 2 microM), similar to that observed in human liver microsomes (apparent Km 0.8 microM). Dronabinol 68-78 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 10-16 16112652-7 2005 Given the high affinity of CYP2C9 for the hydroxylation of delta9-THC, we evaluated the potential for an interaction between delta9-THC, 11-hydroxy-delta9-THC, or 11-nor-9-carboxy-delta9-THC and the CYP2C9 substrate, phenytoin. Dronabinol 59-69 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 27-33 16112652-8 2005 Surprisingly, delta9-THC increased the rate of phenytoin hydroxylation in human liver microsomes and expressed CYP2C9 enzyme. Dronabinol 14-24 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 111-117 34493602-8 2021 These data suggest that cannabinoids and major THC metabolites are able to inhibit the activities of multiple CYP enzymes, and basic static modelling of these data suggest the possibility of pharmacokinetic interactions between these cannabinoids and xenobiotics extensively metabolized by CYP2B6, CYP2C9 and CYP2D6. Dronabinol 47-50 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 298-304 35370140-3 2022 To populate a THC/11-OH-THC PBPK model, we previously characterized the depletion clearance of THC (by CYP2C9) and 11-OH-THC (by UGT, CYP3A, and CYP2C9) in adult human liver microsomes. Dronabinol 14-17 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 103-109 35370140-3 2022 To populate a THC/11-OH-THC PBPK model, we previously characterized the depletion clearance of THC (by CYP2C9) and 11-OH-THC (by UGT, CYP3A, and CYP2C9) in adult human liver microsomes. Dronabinol 14-17 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 145-151 35370140-3 2022 To populate a THC/11-OH-THC PBPK model, we previously characterized the depletion clearance of THC (by CYP2C9) and 11-OH-THC (by UGT, CYP3A, and CYP2C9) in adult human liver microsomes. Dronabinol 95-98 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 103-109 35370140-3 2022 To populate a THC/11-OH-THC PBPK model, we previously characterized the depletion clearance of THC (by CYP2C9) and 11-OH-THC (by UGT, CYP3A, and CYP2C9) in adult human liver microsomes. Dronabinol 95-98 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 145-151 35115300-8 2022 Oral (130 mg) or inhaled (75 mg) THC was predicted to precipitate interactions with drugs predominately metabolized by CYP2C9 (diclofenac, 6.6 or 2.3, respectively) >3A (midazolam, 1.8) >1A2 (theophylline, 1.4). Dronabinol 33-36 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 119-125 32712703-8 2020 In addition, this study showed significantly higher values in the ratio of Delta9-THC/Delta9-THC-COOH for the carriers of the CYP2C9 variants CYP2C9*2 and CYP2C9*3 compared with the carriers of the corresponding wild-type alleles. Dronabinol 82-85 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 126-132 32712703-8 2020 In addition, this study showed significantly higher values in the ratio of Delta9-THC/Delta9-THC-COOH for the carriers of the CYP2C9 variants CYP2C9*2 and CYP2C9*3 compared with the carriers of the corresponding wild-type alleles. Dronabinol 82-85 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 142-148 32712703-8 2020 In addition, this study showed significantly higher values in the ratio of Delta9-THC/Delta9-THC-COOH for the carriers of the CYP2C9 variants CYP2C9*2 and CYP2C9*3 compared with the carriers of the corresponding wild-type alleles. Dronabinol 82-85 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 142-148 32712703-8 2020 In addition, this study showed significantly higher values in the ratio of Delta9-THC/Delta9-THC-COOH for the carriers of the CYP2C9 variants CYP2C9*2 and CYP2C9*3 compared with the carriers of the corresponding wild-type alleles. Dronabinol 93-96 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 126-132 32712703-8 2020 In addition, this study showed significantly higher values in the ratio of Delta9-THC/Delta9-THC-COOH for the carriers of the CYP2C9 variants CYP2C9*2 and CYP2C9*3 compared with the carriers of the corresponding wild-type alleles. Dronabinol 93-96 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 142-148 32712703-8 2020 In addition, this study showed significantly higher values in the ratio of Delta9-THC/Delta9-THC-COOH for the carriers of the CYP2C9 variants CYP2C9*2 and CYP2C9*3 compared with the carriers of the corresponding wild-type alleles. Dronabinol 93-96 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 142-148